Alpine Associates Management’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Alpine Associates Management’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,278,454	Closed	-$12.8M	–	54
2023 Q4	$12.8M	Buy	+1,278,454	New	+$5.8M	0.66%	29

Alpine Associates Management's GRCL Position: Q1 2024 in Review

Alpine Associates Management sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 1,278,454 shares — an estimated $12.8M sold.

Alpine Associates Management first reported a position in GRCL in Q4 2023 and held it in 1 quarter. The position peaked at $12.8M in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Alpine Associates Management reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Alpine Associates Management sold 1,278,454 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $12.8M.
Alpine Associates Management first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2023 and held it in 1 quarter.
Alpine Associates Management's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $12.8M in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Alpine Associates Management's 13F filing for Q1 2024, filed 9 May 2024.